Abbott Plans Spin-Off of Nutrition Business Into Independent Company
Abbott is set to split its Nutrition division into a standalone entity, enhancing growth opportunities for both firms.
Abbott Laboratories, a prominent player in the healthcare sector, has announced its plan to separate its Nutrition business into an independent, publicly traded entity. This strategic move aims to maximize growth opportunities while enhancing value for both organizations.
Empowering Growth in Nutrition
The new Nutrition company is expected to emerge as a leader in the growing healthy nutrition sector, boasting an impressive annual revenue of around $8.5 billion. The company will present a vast array of well-regarded brands including Similac, PediaSure, Pedialyte, Glucerna, and Ensure.
Strategic Development for Both Companies
Robert B. Ford, Abbott’s chairman and CEO, stated, "This separation is intended to benefit both Abbott and the new Nutrition company. By allowing the Nutrition business to operate independently, it can more efficiently allocate its resources to address evolving consumer demands in health and nutrition." In contrast, Abbott will continue to focus on its core areas including medical devices and diagnostics, which represent significant growth prospects.
The separation is well-timed as both companies have differing investment strategies, growth trajectories, and innovation cycles. By tailoring their focus, they can capitalize on unique opportunities more effectively.
Focus on Innovation and Consumer Needs
The Nutrition company, with a workforce of about 16,000 across 14 manufacturing facilities, is positioned to meet rising consumer health and nutritional needs. This independent firm will concentrate on innovation and enhancing its product offerings, backed by scientific research and professional endorsements.
Abbott's nutrition portfolio remains notable for its leading brands. For instance, Ensure holds the title of the top adult nutrition drink globally, while both PediaSure and Glucerna dominate their respective categories for pediatric and diabetes management nutrition. The company has already launched 10 new products in the first half of 2026, emphasizing its commitment to innovation and responding to market demands.
Leadership in the New Era
Daniel Salvadori, who currently serves as Executive Vice President, will lead the newly formed Nutrition company as its CEO. Salvadori brings extensive experience from his tenure at Abbott since 2014, indicating strong leadership for the upcoming entity.
Overview of Abbott Post-Separation
Post-separation, Abbott will maintain its strong position as one of the largest healthcare companies globally, projecting revenues of approximately $42 billion. The focus will shift to its diverse portfolio, which includes market-leading positions in diagnostics, medical devices, and chronic disease management solutions.
The transaction will unfold as a tax-free distribution to Abbott shareholders, expected to be completed by the end of 2027, contingent upon regulatory approvals and other customary conditions. It is designed to ensure that, upon the separation’s conclusion, shareholders will possess shares in both entities.
Abbott anticipates that the total dividends from both the current and new Nutrition company will match Abbott’s dividends at the time of separation, reinforcing its commitment to shareholder value.
Looking Ahead
As Abbott engages with its stakeholders, a dedicated conference call is scheduled for today to discuss this pivotal transaction. The anticipated separation symbolizes a significant realignment that will allow both Abbott and the Nutrition company to thrive in their respective markets.
Shareholders can stay updated on the progress and details of the separation through Abbott’s investor relations portal.
